| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 16 | 13 | 14 | 14 | 12 | 9 | 8 | 13 | 16 | 12 | 12 | 11 | 10 | 14 | 10 |
| Expenses | 15 | 12 | 13 | 12 | 11 | 8 | 6 | 12 | 15 | 11 | 12 | 9 | 9 | 13 | 9 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit % | 4 % | 8 % | 9 % | 11 % | 8 % | 16 % | 21 % | 5 % | 2 % | 7 % | 7 % | 13 % | 10 % | 7 % | 11 % |
| Depreciation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 0 | 0 | 0 | 1 | 0 | 1 | 1 | -0 | -1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 1 | 1 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS in ₹ | 0.03 | 0.21 | 0.21 | 0.52 | 0.17 | 0.53 | 0.60 | -0.24 | -0.34 | 0.03 | 0.04 | 0.23 | 0.04 | 0.12 | 0.19 |
Concord Drugs
Concord Drugs
81.35
-1.86
(-2.24%)
Q1 Quarterly Results are out. Check out the updated financials2 days ago
View
Key Fundamentals
Market Cap
81.34 Cr
EPS
0.34
PE Ratio
143.47
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
92.52
52 Week Low
26.10
PB Ratio
2.42
Debt to Equity
0.54
Sector
Pharmaceuticals Actual
Company News
View All News
Concord Drugs Limited Completes Preferential Allotment of Equity Shares and Convertible Warrants
Today
TodayConcord Drugs Limited's Board approved the allotment of 31,75,000 equity shares at Rs. 36.30 per share raising Rs. 11,52,52,500 and 20,25,000 convertible warrants aggregating Rs. 7,35,07,500. The allotments were made to promoters and public investors on preferential basis, with warrants convertible within 18 months from allotment date.
Concord Drugs Limited Reports Quarterly Financial Results for Period Ended September 30, 20256 days ago
6 days agoConcord Drugs Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, showing revenue from operations of Rs 2,345.87 lakhs and net profit of Rs 30.53 lakhs for the half year period. The pharmaceutical company's results were reviewed by the Audit Committee and auditors, with earnings per share of Rs 0.31 for the reporting period.
Concord Drugs Limited reported consolidated revenue of Rs 1,360.64 lakhs for the quarter ended June 30, 2025, representing growth from Rs 1,039.17 lakhs in the previous quarter and Rs 1,169.29 lakhs in the same quarter last year. The company's consolidated net profit increased to Rs 11.77 lakhs compared to Rs 3.90 lakhs in the previous quarter and Rs 2.73 lakhs in the corresponding quarter of the previous year. On a standalone basis, revenue reached Rs 1,338.35 lakhs with net profit of Rs 11.14 lakhs. The company's basic earnings per share improved to Rs 0.12 for the quarter. The Board of Directors approved these unaudited financial results at their meeting held on August 8, 2025. The consolidated results include subsidiary Proton Remedies Private Limited, which contributed revenues of Rs 40.44 lakhs and net profit of Rs 0.62 lakhs. The company reported no defaults on loans or debt securities.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,777.40 | #1 4,26,457.80 | 40.83 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 71.49 | |
6,462.50 | 1,71,559.07 | 68.94 | 9,712.00 | 18.67 | 2,191 | 35.10 | 47.34 | |
3,721.40 | 1,25,949.09 | 58.99 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.89 | |
1,529.20 | 1,23,521.75 | 22.69 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.01 | |
1,248.60 | 1,04,209.87 | #1 18.19 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.56 | |
928.00 | 93,378.51 | 18.62 | 23,511.00 | 18.55 | 4,615 | 34.60 | 33.23 | |
2,030.80 | 92,757.71 | 21.28 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 58.77 | |
2,239.50 | 92,437.26 | 51.73 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.96 | |
1,207.70 | 70,143.41 | 21.12 | 32,345.60 | 9.43 | 3,484 | 3.81 | 63.26 | |
5,700.00 | 68,152.05 | 28.44 | 13,458.30 | 3.70 | 2,216 | 10.98 | 60.35 |
Growth Rate
Revenue Growth
0.89 %
Net Income Growth
-40.00 %
Cash Flow Change
370.89 %
ROE
-29.29 %
ROCE
5.76 %
EBITDA Margin (Avg.)
1.66 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 56 | 58 | 59 | 65 |
| Fixed Assets | 14 | 13 | 12 | 12 |
| Current Assets | 42 | 44 | 38 | 41 |
| Capital Work in Progress | 1 | 1 | 2 | 2 |
| Investments | 0 | 1 | 1 | 1 |
| Other Assets | 42 | 44 | 45 | 50 |
| Total Liabilities | 56 | 58 | 59 | 65 |
| Current Liabilities | 24 | 22 | 21 | 26 |
| Non Current Liabilities | 4 | 5 | 4 | 5 |
| Total Equity | 28 | 32 | 34 | 34 |
| Reserve & Surplus | 20 | 22 | 24 | 24 |
| Share Capital | 9 | 9 | 10 | 10 |
Cash Flow
| Cash Flow | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 0 | 0 |
| Investing Activities | -2 | -2 | -1 | -2 |
| Operating Activities | 1 | 2 | 1 | 4 |
| Financing Activities | 2 | 1 | 0 | -1 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Oct 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 44.38 % | 49.00 % | 49.00 % | 49.00 % | 49.00 % | 49.00 % | 49.00 % | 49.00 % | 52.13 % | 52.13 % | 52.13 % | 55.41 % | 55.41 % | 55.41 % | 55.41 % | 54.39 % | 54.39 % | 54.39 % | 54.39 % | 54.39 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 54.90 % | 50.05 % | 50.05 % | 50.47 % | 50.65 % | 50.68 % | 50.67 % | 50.71 % | 47.60 % | 47.59 % | 47.54 % | 44.29 % | 44.27 % | 44.28 % | 44.30 % | 45.11 % | 45.11 % | 43.33 % | 42.57 % | 44.95 % |
| Others | 0.73 % | 0.95 % | 0.95 % | 0.53 % | 0.35 % | 0.32 % | 0.33 % | 0.29 % | 0.27 % | 0.28 % | 0.33 % | 0.30 % | 0.32 % | 0.31 % | 0.29 % | 0.50 % | 0.50 % | 2.28 % | 3.04 % | 0.66 % |
| No of Share Holders | 2,173 | 2,826 | 2,826 | 3,071 | 3,047 | 3,036 | 3,188 | 3,321 | 3,215 | 3,198 | 3,957 | 3,963 | 4,032 | 4,734 | 4,755 | 5,073 | 5,073 | 5,252 | 5,189 | 4,718 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 37.89 | 37.27 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 38.11 | 36.87 |
| 11 Jan 2025 | Quarterly Result Announcement | NA | 11 Jan 2025 | 37.38 | 36.71 |
| 23 May 2025 | Quarterly Result Announcement | NA | 23 May 2025 | 31.98 | 31.97 |
| 30 Jul 2025 |  Extraordinary General Meeting | NA | 30 Jul 2025 | 51.45 | 56.00 |
| 31 Jul 2025 | Extraordinary General Meeting | NA | 31 Jul 2025 | 55.48 | 56.00 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 57.12 | 55.84 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 68.60 | 65.40 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 67.01 | 88.15 |
Announcements
Board Meeting Outcome for Outcome Of Board Meeting For Allotment Of Equity Shares And Convertible Warrants2 hours ago
2 hours agoAnnouncement under Regulation 30 (LODR)-Allotment2 hours ago
2 hours agoFinancial Results For Quarter Ended 30 Sep 20257 days ago
7 days agoBoard Meeting Outcome for Outcome Of Board Meeting7 days ago
7 days agoBoard Meeting Intimation for Quarterly ResultsNov 04, 2025
Nov 04, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Sep 30, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 11, 2025
Sep 11, 2025Reg. 34 (1) Annual Report.Sep 09, 2025
Sep 09, 2025Letter To ShareholdersSep 08, 2025
Sep 08, 2025Annual ReportSep 08, 2025
Sep 08, 2025Notice For AGMSep 08, 2025
Sep 08, 2025Record Date For AGMSep 08, 2025
Sep 08, 2025Book Closure For AGMSep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 08, 2025
Sep 08, 2025Board Meeting Outcome for Out Come Of Board MeetingSep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 11, 2025
Aug 11, 2025Financial Results For Quarter Ending 30 June 2025Aug 08, 2025
Aug 08, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 08, 2025
Aug 08, 2025Board Meeting Intimation for Quarterly ResultsAug 01, 2025
Aug 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 01, 2025
Aug 01, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMJul 31, 2025
Jul 31, 2025Corrigendum To The Notice Of EGMJul 22, 2025
Jul 22, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Notice Of EGMJul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJul 03, 2025
Jul 03, 2025Board Meeting Outcome for Out Come Of Board MeetingJul 03, 2025
Jul 03, 2025Clarification Letter Sought From BSEJul 02, 2025
Jul 02, 2025Clarification sought from Concord Drugs LtdJul 02, 2025
Jul 02, 2025Board Meeting Intimation for Issue Of Shares Through Preferential AllotmentJun 30, 2025
Jun 30, 2025Board Meeting Outcome for Outcome Of Board MeetingJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Board Meeting Intimation for Considering And Approval Of Preferential IssueJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Financial Results For Quarter And Financial Year Ending March 31 St 2025.May 23, 2025
May 23, 2025Board Meeting Outcome for Board Meeting Outcome For Audited Results To Consider Audited Results For Year Ending March 31St 2025May 23, 2025
May 23, 2025Board Meeting Intimation for Consideration And Approval Of Audited ResultsMay 16, 2025
May 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Apr 15, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Board Meeting Outcome for Outcome Of Board MeetingMar 17, 2025
Mar 17, 2025Board Meeting Intimation for Reschedule Of Board MeetingMar 13, 2025
Mar 13, 2025Board Meeting Intimation for To Consider Fund Raising By Way Of Preferential IssueMar 04, 2025
Mar 04, 2025Integrated Filing (Financial)Jan 27, 2025
Jan 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 17, 2025
Jan 17, 2025Board Meeting Outcome for Outcome Of Board MeetingJan 11, 2025
Jan 11, 2025Financial Results For 31St December2024Jan 11, 2025
Jan 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Jan 07, 2025Technical Indicators
RSI(14)
Neutral 59.82
ATR(14)
Volatile 5.38
STOCH(9,6)
Neutral 72.98
STOCH RSI(14)
Neutral 56.10
MACD(12,26)
Bullish 0.63
ADX(14)
Weak Trend 24.57
UO(9)
Bearish 51.00
ROC(12)
Uptrend And Accelerating 21.40
WillR(14)
Neutral -40.21
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
